Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The primary aim is to collect data to determine the correct effect size on the primary
outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic
acid and omega-3 fatty acids can improve cognitive function in people with multiple sclerosis
that have cognitive dysfunction.